Progress and Development of Three Types of Live Attenuated Vaccines for Dengue Fever
DOI:
https://doi.org/10.54097/hset.v8i.1204Keywords:
Dengue fever, live attenuated vaccines.Abstract
Dengue fever is a disease spread by mosquitoes infected with the dengue virus (DENV) that bite people. It is produced by any of the four serotypes of DENV. Dengue fever has become one of the most widespread mosquito-borne infectious diseases in the world. According to the World Health Organization (WHO) dengue fever is a serious global public health concern. To suppress the spread of dengue fever and reduce the social, medical, and economic burden brought by dengue fever, vaccination is an effective measure to prevent the disease. Research teams around the world have worked on the development of a dengue vaccine for many years. At present, three live attenuated vaccines have made great progress and entered the final stage of clinical trials. In order to enable dengue vaccine researchers to grasp the latest research status and promote faster development of the dengue vaccine, this paper provided a comprehensive overview of the research progress of three different live attenuated vaccines: CYD-TDV, TAK-003, and TV003/005.
Downloads
References
Ferreira-de-Lima, V. H., & Lima-Camara, T. N., Natural vertical transmission of dengue virus in Aedes aegypti and Aedes albopictus: a systematic review. Parasites & vectors, 11 (1), 2018, pp. 77. https://doi.org/10.1186/s13071-018-2643-9
Gubler D. J., Dengue and dengue hemorrhagic fever. Clinical microbiology reviews, 11 (3), 1998, pp. 480–496. https://doi.org/10.1128/CMR.11.3.480
Chen, L. H., & Wilson, M. E., Update on non-vector transmission of dengue: relevant studies with Zika and other flaviviruses. Tropical diseases, travel medicine and vaccines, 2, 2016, pp. 15. https://doi.org/10.1186/s40794-016-0032-y
Prompetchara, E. , Ketloy, C. , Thomas, S. J. , & Ruxrungtham, K. , Dengue vaccine: global development update. Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand, 38 (3), 2020, pp. 178-185. https://journals.asm.org/doi/10.1128/JVI.76.16.8408-8419.2002
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., Myers, M. F., George, D. B., Jaenisch, T., Wint, G. R., Simmons, C. P., Scott, T. W., Farrar, J. J., & Hay, S. I., The global distribution and burden of dengue. Nature, 496 (7446), 2013, pp. 504–507. https://doi.org/10.1038/nature12060
https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
Buonsenso, D., Barone, G., Onesimo, R., Calzedda, R., Chiaretti, A., & Valentini, P., The re-emergence of dengue virus in non-endemic countries: a case series. BMC research notes, 7, 2014, pp.596. https://doi.org/10.1186/1756-0500-7-596
Bhadra, S., Dengue guidelines for diagnosis, treatment, prevention and control. 2020 https://www.researchgate.net/publication/342215778_Dengue_guidelines_for_diagnosis_treatment_prevention_and_control
Bull, J. J., & Turelli, M., Wolbachia versus dengue: evolutionary forecasts. Evolution Medicine & Public Health, 2013(1), pp. 197. https://pubmed.ncbi.nlm.nih.gov/24481199/
Martins, A., Correia, F., Cavalcanti, L., & Alencar, C. H., Dengue in northeastern Brazil: a spatial and temporal perspective. Revista da Sociedade Brasileira de Medicina Tropical, 53, 2020, e20200435. https://doi.org/10.1590/0037-8682-0435-2020
Guzman MG, Halstead SB, Artsob H, et al., Dengue: a continuing global threat [J]. Nat Rev Microbiol, (12 Suppl), 2010: S7-16.DOI:10.1038/nrmicro2460.
Christine, A., King, Robert, Anderson, & Jean, et al., Dengue virus selectively induces human mast cell chemokine production. J. Virol., 76(16), 2002, pp. 8408-8419. https://journals.asm.org/doi/10.1128/JVI.76.16.8408-8419.2002
Redoni, M., Yacoub, S., Rivino, L., Giacobbe, D. R., Luzzati, R., & Di Bella, S., Dengue: Status of current and under‐development vaccines. Reviews in Medical Virology, 30 (4). 2020 https://doi.org/10.1002/rmv.2101
Dengvaxia dengue vaccine. Precision Vaccinations. (n.d.). Retrieved April 12, 2022, from https://www.precisionvaccinations.com/vaccines/dengvaxia-dengue-vaccine
Tully, D., & Griffiths, C. L., Dengvaxia: the world’s first vaccine for prevention of secondary dengue. Therapeutic Advances in Vaccines and Immunotherapy. 2021. https://doi.org/10.1177/25151355211015839
Glick, B. R., Delovitch, T. L., & Patten, C. L. 2014. In Medical Biotechnology (pp. 644). essay, ASM Press.
Centers for Disease Control and Prevention, Frequently asked questions about the dengue vaccine. Retrieved April 12, 2022, from https://www.cdc.gov/dengue/vaccine/parents/eligibility/faq.html
Capeding, M. R., Tran, N. H., Hadinegoro, S. R., Ismail, H. I., Chotpitayasunondh, T., Chua, M. N., Luong, C. Q., Rusmil, K., Wirawan, D. N., Nallusamy, R., Pitisuttithum, P., Thisyakorn, U., Yoon, I.-K., van der Vliet, D., Langevin, E., Laot, T., Hutagalung, Y., Frago, C., Boaz, M., … Bouckenooghe, A., Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. The Lancet, 384 (9951), 2014, pp. 1358–1365. https://doi.org/10.1016/s0140-6736(14)61060-6
Dayan, G. H., Langevin, E., Forrat, R., Zambrano, B., Noriega, F., Frago, C., Bouckenooghe, A., Machabert, T., Savarino, S., & DiazGranados, C. A., Efficacy after 1 and 2 doses of Cyd-TDV in dengue endemic areas by dengue serostatus. Vaccine, 38 (41), 2020, pp. 6472–6477. https://doi.org/10.1016/j.vaccine.2020.07.056
Ainaa Muhsin, N. I., The Dengue Vaccine Dilemma: Route to prevention – are we there yet? Scientific Malaysian Magazine. Retrieved April 12, 2022, from https://magazine.scientificmalaysian.com/issue-12-2016/dengue-vaccine-dilemma-route-prevention-yet/
Neutralizing antibody definition. Biology Articles, Tutorials & Dictionary Online. (2021, March 1). Retrieved April 12, 2022, from https://www.biologyonline.com/dictionary/neutralizing-antibody
Hukla, R., Ramasamy, V., Shanmugam, R. K., Ahuja, R., & Khanna, N., Antibody-dependent enhancement: A Challenge for developing a safe dengue vaccine. Frontiers in Cellular and Infection Microbiology, 10. 2020. https://doi.org/10.3389/fcimb.2020.572681
Turner, M., Papadimitriou, A., Winkle, P., Segall, N., Levin, M., Doust, M., Johnson, C., Lucksinger, G., Fierro, C., Pickrell, P., Raanan, M., Tricou, V., Borkowski, A., & Wallace, D., Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial. Human Vaccines & Immunotherapeutics, 16(10), 2020, pp. 2456–2464. https://doi.org/10.1080/21645515.2020.1727697
Precision Vaccinations. TAK-003 Dengue Vaccine. 2022, February 3 https://www.precisionvaccinations.com/vaccines/tak-003-dengue-vaccine
Hertanto, Y. J., & Novita, B. D., Efficacy of Live Attenuated Dengue Vaccines: CYD-TDV; TDV (TAK-003) and TV003/TV005. Folia Medica Indonesiana, 57 (4), 2021, pp. 365. https://doi.org/10.20473/fmi.v57i4.21741
Rivera, L., Biswal, S., Sáez-Llorens, X., Reynales, H., López-Medina, E., Borja-Tabora, C., Bravo, L., Sirivichayakul, C., Kosalaraksa, P., Martinez Vargas, L., Yu, D., Watanaveeradej, V., Espinoza, F., Dietze, R., Fernando, L., Wickramasinghe, P., Duarte MoreiraJr, E., Fernando, A. D., Gunasekera, D., . . . Borkowski, A., Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003). Clinical Infectious Diseases. 2021. https://doi.org/10.1093/cid/ciab864
Waickman AT, Victor K, Li T, Hatch K, Rutvisuttinunt W, Medin C, et al. Dissecting the Heterogeneity of DENV Vaccine-Elicited Cellular Immunity Using Single-Cell RNA Sequencing and Metabolic Profiling. Nat Commun 2019, 10 (1): pp. 3666. doi: 10.1038/s41467-019-11634-7
Jue Hou, Weijian Ye and Jianzhu Chen, “Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines”, 24 February 2022, https://doi.org/10.3389/fimmu.2022.840104
Butantin Institute, "Phase III Trial to Evaluate Efficacy and Safety of a Dengue 1, 2, 3, 4 (Attenuated) Vaccine" August 2021, https://clinicaltrials.gov/ct2/show/study/NCT02406729
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
